Park Ha Biological Technology is trading 5.77% up at $2.75 after investors continued responding to its September 11 private placement, which raised approximately $2.97 million through shares and warrants.
- The financing improves working-capital flexibility but introduces potential dilution from immediately exercisable warrants.
- The stock rose 9.24% on September 14, indicating continued momentum and heightened volatility.
- Broader markets are slightly lower, making company-specific financing news the apparent main catalyst.